Xu R - Search Results

1

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.

Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ Jr, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ. Wan C, et al. Among authors: xu r. Cancer Res. 2021 Jan 1;81(1):158-173. doi: 10.1158/0008-5472.CAN-20-1674. Epub 2020 Nov 6. Cancer Res. 2021. PMID: 33158814 Free PMC article.

2

Galectins and Ovarian Cancer.

Shimada C, Xu R, Al-Alem L, Stasenko M, Spriggs DR, Rueda BR. Shimada C, et al. Among authors: xu r. Cancers (Basel). 2020 May 31;12(6):1421. doi: 10.3390/cancers12061421. Cancers (Basel). 2020. PMID: 32486344 Free PMC article. Review.

3

Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.

Mei J, Cai Y, Xu R, Yang X, Zhou W, Wang H, Liu C. Mei J, et al. Among authors: xu r. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211011970. doi: 10.1177/15330338211011970. Technol Cancer Res Treat. 2021. PMID: 33955303 Free PMC article.

4

Formin protein FMNL1 is a biomarker for tumor-infiltrating immune cells and associated with well immunotherapeutic response.

Lu G, Wang H, Xu R, Xu J, An F, Xu H, Nie H, Mei J, Zhan Q, Zhang Q. Lu G, et al. Among authors: xu r, xu h, xu j. J Cancer. 2023 Sep 11;14(16):2978-2989. doi: 10.7150/jca.86965. eCollection 2023. J Cancer. 2023. PMID: 37859818 Free PMC article.

5

Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade.

Mei J, Cai Y, Xu R, Li Q, Chu J, Luo Z, Sun Y, Shi Y, Xu J, Li D, Liang S, Jiang Y, Liu J, Qian Z, Zhou J, Wan M, Yang Y, Zhu Y, Zhang Y, Yin Y. Mei J, et al. Among authors: xu r, xu j. Cancer Commun (Lond). 2024 Mar 20. doi: 10.1002/cac2.12538. Online ahead of print. Cancer Commun (Lond). 2024. PMID: 38507505

6

Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer.

Xu R, Pan J, Mei J, Zhang Q. Xu R, et al. Biomed Res Int. 2020 Jan 9;2020:3948183. doi: 10.1155/2020/3948183. eCollection 2020. Biomed Res Int. 2020. PMID: 32382548 Free PMC article.

7

GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway.

Hu Z, Xu R, Liu J, Zhang Y, Du J, Li W, Zhang W, Li Y, Zhu Y, Gu L. Hu Z, et al. Among authors: xu r. Exp Cell Res. 2013 Aug 1;319(13):1932-1941. doi: 10.1016/j.yexcr.2013.05.028. Epub 2013 Jun 5. Exp Cell Res. 2013. PMID: 23747719 Free article.

8

DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.

Mei J, Huang Y, Hao L, Liu Y, Yan T, Qiu T, Xu R, Xu B, Xiao Z, Jiang X, Hu K, Zhu Y. Mei J, et al. Among authors: xu r, xu b. Pathol Res Pract. 2019 Jul;215(7):152452. doi: 10.1016/j.prp.2019.152452. Epub 2019 May 14. Pathol Res Pract. 2019. PMID: 31104928 Free article.

9

The interplay between HIF-1α and noncoding RNAs in cancer.

Peng X, Gao H, Xu R, Wang H, Mei J, Liu C. Peng X, et al. Among authors: xu r. J Exp Clin Cancer Res. 2020 Feb 3;39(1):27. doi: 10.1186/s13046-020-1535-y. J Exp Clin Cancer Res. 2020. PMID: 32014012 Free PMC article. Review.

10

Correction to: The interplay between HIF-1α and noncoding RNAs in cancer.

Peng X, Gao H, Xu R, Wang H, Mei J, Liu C. Peng X, et al. Among authors: xu r. J Exp Clin Cancer Res. 2020 Mar 3;39(1):45. doi: 10.1186/s13046-020-01544-8. J Exp Clin Cancer Res. 2020. PMID: 32122375 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,414 results

Search Page